Search

Your search keyword '"Pentheroudakis G"' showing total 964 results

Search Constraints

Start Over You searched for: Author "Pentheroudakis G" Remove constraint Author: "Pentheroudakis G"
964 results on '"Pentheroudakis G"'

Search Results

1. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

2. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer

5. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer

6. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

7. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review

8. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

9. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)

11. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer

12. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

13. COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases

14. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

16. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

19. COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)

20. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

21. Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

23. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

25. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

26. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

27. JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions

28. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

29. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

30. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

31. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

32. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

33. Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey

34. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

35. 2107P Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients

36. Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit

37. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

39. Learning lessons from the COVID-19 pandemic for real-world evidence research in oncology—shared perspectives from international consortia

41. Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors : A collaborative work from ESMO real-world data and Digital Health Working Group

42. Real-world evidence contributions to European medicines agency's safety and efficacy evaluations of oncology targeted therapies between 2018-2022

43. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

44. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

45. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

46. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

47. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials

48. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

49. 237P Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: A joint analysis of OnCovid and ESMO-CoCARE registries

50. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe

Catalog

Books, media, physical & digital resources